Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.Smallpox Vaccine: A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)Smallpox: An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)Vaccinia virus: The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.Kidney Transplantation: The transference of a kidney from one human or animal to another.Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).Mycophenolic Acid: An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)Calcineurin: A CALCIUM and CALMODULIN-dependent serine/threonine protein phosphatase that is composed of the calcineurin A catalytic subunit and the calcineurin B regulatory subunit. Calcineurin has been shown to dephosphorylate a number of phosphoproteins including HISTONES; MYOSIN LIGHT CHAIN; and the regulatory subunits of CAMP-DEPENDENT PROTEIN KINASES. It is involved in the regulation of signal transduction and is the target of an important class of immunophilin-immunosuppressive drug complexes.Graft Rejection: An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.Drug Substitution: The practice of replacing one prescribed drug with another that is expected to have the same clinical or psychological effect.Lymphangioleiomyomatosis: A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).Angiomyolipoma: A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)TOR Serine-Threonine Kinases: A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.Graft Survival: The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.Lymphangiomyoma: A tumorlike condition characterized by SMOOTH MUSCLE and ENDOTHELIUM proliferation of LYMPHATIC VESSELS and LYMPH NODES in the MEDIASTINUM and retroperitoneum, also in the lung. It may be manifested by chylous PLEURAL EFFUSION and ASCITES.Injections, Intraocular: The administration of substances into the eye with a hypodermic syringe.Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Chyle: An opaque, milky-white fluid consisting mainly of emulsified fats that passes through the lacteals of the small intestines into the lymphatic system.Liver Transplantation: The transference of a part of or an entire liver from one human or animal to another.Polyenes: Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES.Transplantation, Homologous: Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.Drug-Eluting Stents: Stents that are covered with materials that are embedded with chemicals that are gradually released into the surrounding milieu.CreatinineKidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Drug Monitoring: The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.Islets of Langerhans Transplantation: The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.Drug Implants: Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.Glomerular Filtration Rate: The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.Transplantation: Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.Fluorescence Polarization Immunoassay: Fluoroimmunoassay where detection of the hapten-antibody reaction is based on measurement of the increased polarization of fluorescence-labeled hapten when it is combined with antibody. The assay is very useful for the measurement of small haptenic antigens such as drugs at low concentrations.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Stents: Devices that provide support for tubular structures that are being anastomosed or for body cavities during skin grafting.Immunosuppression: Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.Thrombotic Microangiopathies: Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.Tubulin Modulators: Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.Oxaloacetic Acid: A dicarboxylic acid ketone that is an important metabolic intermediate of the CITRIC ACID CYCLE. It can be converted to ASPARTIC ACID by ASPARTATE TRANSAMINASE.Coated Materials, Biocompatible: Biocompatible materials usually used in dental and bone implants that enhance biologic fixation, thereby increasing the bond strength between the coated material and bone, and minimize possible biological effects that may result from the implant itself.Citrus paradisi: A plant species of the genus CITRUS, family RUTACEAE that produces the familiar grapefruit. There is evidence that grapefruit inhibits CYTOCHROME P-450 CYP3A4, resulting in delayed metabolism and higher blood levels of a variety of drugs.Polycystic Kidney, Autosomal Dominant: Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)Acetic Anhydrides: Compounds used extensively as acetylation, oxidation and dehydrating agents and in the modification of proteins and enzymes.Heart Transplantation: The transference of a heart from one human or animal to another.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Drug Interactions: The action of a drug that may affect the activity, metabolism, or toxicity of another drug.Unrelated Donors: Providers of tissues for transplant to non-related individuals.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Antilymphocyte Serum: Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.Oral Ulcer: A loss of mucous substance of the mouth showing local excavation of the surface, resulting from the sloughing of inflammatory necrotic tissue. It is the result of a variety of causes, e.g., denture irritation, aphthous stomatitis (STOMATITIS, APHTHOUS); NOMA; necrotizing gingivitis (GINGIVITIS, NECROTIZING ULCERATIVE); TOOTHBRUSHING; and various irritants. (From Jablonski, Dictionary of Dentistry, 1992, p842)Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.Kidney Function Tests: Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine.Perivascular Epithelioid Cell Neoplasms: A family of mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These cells do not have a normal anatomic homolog. (From Fletcher CDM, et. al., World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone, 2002).Ribosomal Protein S6 Kinases, 70-kDa: A family of ribosomal protein S6 kinases that are considered the major physiological kinases for RIBOSOMAL PROTEIN S6. Unlike RIBOSOMAL PROTEIN S6 KINASES, 90KDa the proteins in this family are sensitive to the inhibitory effects of RAPAMYCIN and contain a single kinase domain. They are referred to as 70kDa proteins, however ALTERNATIVE SPLICING of mRNAs for proteins in this class also results in 85kDa variants being formed.Paclitaxel: A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.Biliary Fistula: Abnormal passage in any organ of the biliary tract or between biliary organs and other organs.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Clinical Audit: A detailed review and evaluation of selected clinical records by qualified professional personnel to improve the quality of patient care and outcomes. The clinical audit was formally introduced in 1993 into the United Kingdom's National Health Service.Adrenal Cortex HormonesKetoconazole: Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients.Oligomenorrhea: Abnormally infrequent menstruation.Transplantation Conditioning: Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.Respiratory System Agents: Drugs used for their effects on the respiratory system.Mucorales: An order of zygomycetous fungi, usually saprophytic, causing damage to food in storage, but which may cause respiratory infection or MUCORMYCOSIS in persons suffering from other debilitating diseases.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Steroids: A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.Absorbable Implants: Implants constructed of materials designed to be absorbed by the body without producing an immune response. They are usually composed of plastics and are frequently used in orthopedics and orthodontics.Cytochrome P-450 CYP3A: A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN.Living Donors: Non-cadaveric providers of organs for transplant to related or non-related recipients.Benzenesulfonates: Organic salts and esters of benzenesulfonic acid.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Intention to Treat Analysis: Strategy for the analysis of RANDOMIZED CONTROLLED TRIALS AS TOPIC that compares patients in the groups to which they were originally randomly assigned.Graft Occlusion, Vascular: Obstruction of flow in biological or prosthetic vascular grafts.Coronary Angiography: Radiography of the vascular system of the heart muscle after injection of a contrast medium.Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
It is a derivative and prodrug of sirolimus and is sold as Torisel. Temsirolimus is a specific inhibitor of mTOR and interferes ... The recommended dose of temsirolimus is 25 mg IV infused over 30-60 minutes once per week (Wyeth Pharmaceuticals, Inc., 2007). ... Though temsirolimus shows activity on its own, it is also known to be converted to sirolimus (rapamycin) in vivo; therefore, ... Temsirolimus (codenamed CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth ...
... formerly by Wyeth). Sirolimus is indicated for the prevention of organ transplant rejection and for the treatment of ... Sirolimus seems to lower the cancer risk in some transplant patients. Sirolimus was shown to inhibit the progression of dermal ... Sirolimus blocks this pathway. The safety and efficacy of sirolimus treatment of LAM were investigated in clinical trials that ... The antiproliferative effects of sirolimus may have a role in treating cancer. When dosed appropriately, sirolimus can enhance ...
"Wyeth and Amgen heighten warning of life-threatening infections on skin drug Enbrel". Archived from the original on 2008-05-05 ... Wyeth (now part of Pfizer) was the sole marketer of Enbrel outside North America excluding Japan where Takeda Pharmaceuticals ...
Wyeth. *Piperidines. *Chloroarenes. *Benzocycloheptapyridines. *Peripherally selective drugs. *World Health Organization ...
... formerly by Wyeth). Sirolimus is indicated for the prevention of organ transplant rejection and for the treatment of ... Sirolimus seems to lower the cancer risk in some transplant patients. Sirolimus was shown to inhibit the progression of dermal ... Sirolimus blocks this pathway. The safety and efficacy of sirolimus treatment of LAM were investigated in clinical trials that ... The antiproliferative effects of sirolimus may have a role in treating cancer. When dosed appropriately, sirolimus can enhance ...
Rapamune (sirolimus) oral solution. Oral solution of sirolimus. Rapamune (sirolimus) Tablets. For treatment of kidney rejection ... Company: Wyeth. Search by brand name for drugs approved by the Food and Drug Administration (FDA) for sale in the United States ...
Rapamune (sirolimus) Tablets; Wyeth; For treatment of kidney rejection, Approved August 2000 ... Rapamune (sirolimus) Tablets; Wyeth; For treatment of kidney rejection, Approved August 2000 ... Mylotarg (gemtuzumab ozogamicin); Wyeth; For the treatment of CD33 positive acute myeloid leukemia (AML), Approved May 2000 ... Protonix (pantoprazole sodium) Delayed-Release Tablets; Wyeth; For treatment of erosive esophagitis, Approved February 2000 ...
Wyeth Pharmaceuticals July, 2019.. *24.Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug ... Wyeth Pharmaceuticals, Inc. March, 2018.. *28.Manez R, Martin M, Raman D, Silverman D, Jain A, Warty V, Gonzalez-Pinto I, Kusne ... Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 2006 Feb;26(2):289-95. ... Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 2004 Feb 15;77(3):474-5. ...
1.Rapamune (sirolimus) US prescribing information. Wyeth Pharmaceuticals May, 2018.. *2.Kovarik JM, Beyer D, Bizot MN, Jiang Q ... Wyeth Pharmaceuticals, Inc. March, 2018.. *12.Danan G, Descatoire V, Pessayre D. Self-induction by erythromycin of its own ... Sirolimus and erythromycin interaction: two cases. Transplant Proc 2001 May;33(3):2136. ...
Patients with type 1 diabetes who received islet transplantation from a single donor pancreas were insulin independent one year later, according to a study.
Rapamune (sirolimus) complete prescribing information. Wyeth Pharmaceuticals Inc. October 2009 Layout table for additonal ... Sirolimus 0.2% ointment applied topically hs x 12 weeks. Drug: Sirolimus 0.2% Ointment for topical administration hs x 12 weeks ... Sirolimus 0.4% ointment applied topically hs x 12 weeks. Drug: Sirolimus 0.4% Ointment for topical administration hs x 12 weeks ... sirolimus 0.2% ointment, sirolimus 0.4% ointment, or placebo ointment. The randomization is stratified by site. Subjects, or a ...
WYETH-0468X-4420 ( Other Identifier: Wyeth ). First Submitted:. March 20, 2007. First Posted:. March 22, 2007. ... Dose of sirolimus required to achieve target trough sirolimus plasma concentration [ Time Frame: Days 8, 15, 21, 29, 43, 57, 85 ... Sirolimus also may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood ... Drug: sirolimus The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART ...
... and 32-desmethoxy sirolimus were obtained from Wyeth-Ayerst (Pearl River or Rouses Point, NY); [14C]sirolimus was radiolabeled ... demethyl sirolimus;m/z 931.6, sirolimus and isomers;m/z 933.6, hydroxy-demethyl sirolimus;m/z 947.6, hydroxy sirolimus;m/z ... hydroxy sirolimus), 933.6 (hydroxy demethyl sirolimus or dihydro sirolimus), 931.6 (sirolimus and isomers), and 917.6 (demethyl ... Both sirolimus and D2 were detected in the RIC of m/z 931.6. The earlier elution of D2 relative to sirolimus was consistent ...
Tacrolimus (Prograf®; Fujisawa Healthcare Inc., Deerfield, IL) or sirolimus (Rapamune®; Wyeth Pharmaceuticals, Collegeville, PA ... for the Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: ... with sirolimus, 96% with tacrolimus; p = 0.42) as was graft survival (94% sirolimus vs. 92% tacrolimus, p = 0.95). The ... but fewer chronic vascular changes in the sirolimus group. This study shows that a CNI-free regimen using sirolimus-MMF- ...
Rapamune, manufactured by Wyeth. Reference and Publication Information. United Network for Organ Sharing (UNOS) is committed to ... Taking sirolimus. *Take sirolimus exactly as directed by your doctor. If you do not understand these directions, ask your ... Sirolimus and pregnancy. Although sirolimus has not been studied in pregnant women, it is not recommended for use during ... How sirolimus works. Sirolimus works by preventing the white blood cells from getting rid of the transplanted organ. ...
Rapamune® (sirolimus) and Torisel® (temsirolimus) are registered trademarks of Wyeth Pharmaceuticals Inc. ... Patients should tell their healthcare provider before taking Afinitor if they are allergic to sirolimus (Rapamune®#) or ...
Wyeth-AHP, Zug, Switzerland) in the drinking water; BDL animals in the nontreatment group that received no drug treatment (BDL ... Shihab FS, Bennett WM, Yi H, Choi SO, and Andoh TF (2004) Sirolimus increases transforming growth factor-beta1 expression and ... Long-Term Treatment of Bile Duct-Ligated Rats with Rapamycin (Sirolimus) Significantly Attenuates Liver Fibrosis: Analysis of ... Long-Term Treatment of Bile Duct-Ligated Rats with Rapamycin (Sirolimus) Significantly Attenuates Liver Fibrosis: Analysis of ...
Wyeth Pharmaceuticals, Inc. 2004.. *↵ Taylor PJ, Johnson AG. Quantitative analysis of sirolimus (rapamycin) in blood by high- ... Rapamycin (sirolimus) has a "black-box warning" from the Food and Drug Administration stating that its use is associated with ... Determination of sirolimus (rapamycin) in murine whole blood. Samples were prepared according to the method of Taylor and ... Rapamune (sirolimus) Oral Solution/Tablets, Package Insert. ... Rapamune (sirolimus) Oral Solution/Tablets, Package Insert. ...
Rapamune® (sirolimus) oral solution prescribing informationPhiladelphia, Wyeth Laboratories, 1999.. *↵ Napoli KL. The FTY720 ... Sirolimus and everolimus. Sirolimus (rapamycin) is a hydrophobic, macrocycliclactone produced by the actinomycete Streptomyces ... This is in contrast with sirolimus, which must be administered 4 h apart from CsA, due to significant pharmacokinetic ... sirolimus and everolimus exert their immunosuppressive effects by blocking growth factor-driven cell proliferation of both ...
Pfizer, which bought Wyeth in 2009, markets it under the name Rapamune (sirolimus). ... Wyeths leadership took the helm of the new Wyeth-Ayerst Laboratories, and Sehgal felt he might find his new bosses more ... Wyeths medicinal chemistry and pharmacology teams also took an interest in rapamycin, recalls Magid Abou-Gharbia, who spent 26 ... Wyeth wasnt the only company that zeroed in on rapamycins cyclohexane ring hydroxyl handle. Chemists at Novartis tacked a ...
Everolimus is a derivative of sirolimus (rapamycin, Rapamune, Wyeth/Pfizer).. Source: MedPage Today, February 18, 2013 ...
Sirolimus, RAPAMUNE.RTM., Wyeth), Lapatinib (TYKERB.RTM., GSK572016, Glaxo Smith Kline), Lonafarnib (SCH 66336), Sorafenib ( ...
The authors have previously received research support from Wyeth, which markets sirolimus. ... But patients on sirolimus also had a significant reduction in uric acid, from 7.6 ± 2.4 to 6.2 ± 1.9 mg/dl (P=0.0007). Uric ... The authors found that among patients switched to sirolimus, GFR increased from 47.0 ± 17.4 to 57.2 ± 23 ml/minute (P< 0.005 ... The authors saw a significant increase in proteinuria following conversion to sirolimus, from 298 ± 623 to 473 ± 764 mg/day ( ...
It is marketed under the trade name Rapamune by Wyeth. ... Sirolimus is a macrolide ("-mycin") first discovered as a ... Sirolimus. Revision as of 20:01, 27 September 2011 by WikiBot. (talk , contribs) (Protected Sirolimus: Protecting pages from ... The anti-proliferative effects of sirolimus may have a role in treating cancer. Recently, it was shown that sirolimus inhibited ... The mode of action of sirolimus is to bind the cytosolic protein FK-binding protein 12 (FKBP12) in a manner similar to ...
Trial Wyeth disease - modifying therapy phase 2 study / Sirolimus 2004-2005. * Trial Etoricoxib and cardiovascular interaction ...
Rapamune® (sirolimus) and Torisel® (temsirolimus) are registered trademarks of Wyeth Pharmaceuticals Inc. ... Patients should tell their health care provider before taking Afinitor if they are allergic to sirolimus (Rapamune®) or ...
In the SIK group, immunosuppression was carried out with tacrolimus and sirolimus (Wyeth Pharma, Zug, Switzerland), according ... Sirolimus was later changed to mycophenolate mofetil because of the high rate of side effects reported for sirolimus (8). ... to the Edmonton protocol (2). The target long-term trough levels were 7-10 μg/L for sirolimus and 3-6 μg/L for tacrolimus. ...
Sirolimus is a Wyeth product marketed under the brand name Rapamune and licensed to Cordis. Sirolimus, an immunosuppressant, is ... The Cordis division of Johnson & Johnson won the race this year with a product named Cypher which uses the drug Sirolimus ( ...
It is a derivative and prodrug of sirolimus and is sold as Torisel. Temsirolimus is a specific inhibitor of mTOR and interferes ... The recommended dose of temsirolimus is 25 mg IV infused over 30-60 minutes once per week (Wyeth Pharmaceuticals, Inc., 2007). ... Though temsirolimus shows activity on its own, it is also known to be converted to sirolimus (rapamycin) in vivo; therefore, ... Temsirolimus (codenamed CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth ...
  • Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. (medkoo.com)
  • Sirolimus delivered as either an intravitreal or subconjunctival injection has demonstrated bioactivity as an immunomodulatory and corticosteroid-sparing agent in reducing vitreous haze and cells, improving visual acuity, and in decreasing the need for systemic corticosteroids. (springeropen.com)
  • There was no significant difference in cardiac rejection rates between the sirolimus-treated patients and controls, and no difference in cardiac allograft function. (medpagetoday.com)
  • In the second study, Dr. Kuswaha and colleagues used three-dimensional intravascular ultrasound to gauge the progression of cardiac allograft vasculopathy in 29 patients on sirolimus-based immunosuppression for nearly four years. (medpagetoday.com)
  • At 1 year, chronicity using the Banff schema showed no difference in interstitial, tubular or glomerular changes, but fewer chronic vascular changes in the sirolimus group. (wiley.com)
  • Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. (bio-medicine.org)
  • Using Caco-2 cell monolayers expressing CYP3A4, we investigated the interplay between metabolism and transport on the first-pass intestinal extraction of the immunosuppressant sirolimus, a CYP3A4/P-glycoprotein (P-gp) substrate. (aspetjournals.org)
  • Modified Caco-2 cells metabolized [ 14 C]sirolimus to the predicted amounts of CYP3A4-mediated products based on CYP3A4 content, which was ∼20% of that measured in human small intestinal mucosal homogenate. (aspetjournals.org)
  • Sirolimus is a macrolide ( "-mycin" ) first discovered as a product of the bacterium Streptomyces hygroscopicus in a soil sample from an island called Rapa Nui, better known as Easter Island. (wikidoc.org)
  • Several large clinical studies have demonstrated lower restenosis rates in patients treated with sirolimus-eluting stents when compared to bare-metal stents, resulting in fewer repeat procedures. (wikipedia.org)
  • Evaluate the clinical response of KS in patients treated with this sirolimus. (clinicaltrials.gov)
  • MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX News Network/ -- An analysis of data from the Western Denmark Heart Registry found that patients who received the CYPHER(R) Sirolimus-eluting Coronary Stent to open a clogged artery were less likely to need another procedure at that same lesion site (a clinical event called target lesion revascularization or TLR) than patients who received a Taxus Stent. (bio-medicine.org)
  • In this preliminary analysis, we present the 4-month clinical, angiographic, and ultrasonographic results of the first 15 patients treated with the novel Vestasync nonpolymer-based sirolimus-eluting stent. (onlinejacc.org)
  • In this proof-of-concept study, we provided clear-cut evidence that in patients with ADPKD, 6 months of sirolimus therapy halted the growth of renal cysts and increased the volume of seemingly healthy kidney parenchyma with acceptable adverse effects," write lead author Norberto Perico, MD, from the Clinical Research Center for Rare Diseases, Mario Negri Institute for Pharmacological Research, Bergamo, Italy, and colleagues. (24drs.com)
  • RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. (clinicaltrials.gov)
  • The authors saw a significant increase in proteinuria following conversion to sirolimus, from 298 ± 623 to 473 ± 764 mg/day ( P =0.001), compared with no change in controls. (medpagetoday.com)